绥美凯服用量是多少？

On January 20, 2018, GlaxoSmithKline China (GSK China) announced that its single-tablet compound preparation (chemical name: doptabalamid tablets) was officially launched in mainland China. This is the best-selling AIDS drug in the world in the past five years, and it is also an important part of GSK China in the field of AIDS in recent years. Since Suimeikan was approved for marketing in 2014, its sales have increased by leaps and bounds. In 2016, it ranked first in the global AIDS drug rankings, becoming the best-performing business segment of GSK. Today let’s find out how much Suimeikai should be taken?

The ingredients of Inbec are dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. Three drugs are used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). 

The dosage of Suimeike is quite special, the weight of adults and teenagers is at least 40kg. Trimax is a fixed-dose tablet and cannot be used in patients who require dose adjustment. If one of the active ingredients needs to be discontinued or its dose adjusted, a separate formulation of dolutegravir, abacavir or lamivudine can be used. If you need to change medications, please consult your doctor first. 

For adults and adolescents, the recommended dose of Trimax is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. 

If the patient misses a dose of Suimei Kai, and there is more than 4 hours left before the next dose, he should take Sui Mei Kai as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

Suimeike is a film-coated tablet that appears white or off-white after the coating is removed. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B*5701 allele, he should not take products containing abacavir.

The above is the content of the dosage, I hope it can help you!